Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

REDEFINE 1

Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 3400

NCT05567796

Y axis: Change in body weight from baseline, %

0-5-10-15-20-250481216202436486072Cagrisema, week 68, -20.4%CagrisemaPlacebo s.c., week 68, -3%Placebo s.c.

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Cagrisema: week 68 -20.4%
  • Placebo s.c.: week 68 -3%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.